Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer

Authors: Qin Jiang, Shuai Pang, Yifang Xia, Hongmei Sun, Yingying Yu

Journal: Evidence-Based Complementary and Alternative Medicine

Study Design: Randomized controlled trial

Participants: 160 patients with recurrent ovarian cancer

Intervention: The patients were divided into two groups:

• Control group (n = 80): Received chemotherapy (Taxol liposome and Carboplatin)
• Observation group (n = 80): Received lentinan combined with (125)I brachytherapy in addition to the same chemotherapy as the control group.

Outcome Measures:

• Levels of tumor markers (CA125, CA199, and CA724)
• Proportion of immune cells in peripheral blood (CD3+, CD3+CD4+, CD3+CD8+, CD4+/CD8+, CD3−CD56+, CD3+CD56+, CD4+CD25highFOXP3+, CD14+, and CD19+ B cells)
• Levels of immunoglobulin (IgG, IgM, and IgA)
• Levels of hemoglobin (HGB), white blood cells (WBC), platelets (PLT), neutrophils (NEU), and red blood cells (RBC)
• Disease control rate (DCR)
• Overall survival
• Karnofsky Performance Scale (KPS) score
• Quality of life scale (QOL) score
• Incidence of adverse reactions (hemoglobin reduction, leukopenia, aglobulia, granulocytopenia, nausea and vomiting, hepatorenal toxicity, and neurovirulence)

Summary: The study aimed to investigate the clinical value of lentinan combined with (125)I brachytherapy in the treatment of recurrent ovarian cancer. The results showed that the combination therapy was more effective than chemotherapy alone in terms of DCR and overall survival. The combination therapy also improved immune function, quality of life, and reduced the incidence of adverse reactions. The study concluded that lentinan combined with (125)I brachytherapy is a promising treatment option for recurrent ovarian cancer.